Table 1.
Clinical and pathological characteristics of patients
| Variables | Total (n = 140) | Group 1 (n = 103) | Group 2 (n = 21) | Group 3 (n = 11) | Group 4 (n = 5) | P* |
|---|---|---|---|---|---|---|
| Age | 0.356 | |||||
| Mean | 59.3±7.4 | 58.8±7.1 | 60.6±8.4 | 62.3±8.2 | 56.8±7.8 | |
| Median (range) | 59 (41–77) | 59 (41–75) | 60 (45–77) | 63 (43–75) | 56 (49–67) | |
| Body mass index (kg m−2) | 28.5±5.2 | 28.2±4.2 | 29.2±4.3 | 30.7±11.7 | 25.5±4.0 | 0.259 |
| Preoperative PSA (ng ml−1) | 5.6±2.7 | 5.3±2.3 | 6.5±3.9 | 6.2±3.3 | 6.2±2.3 | 0.197 |
| Preoperative AUASS | 8.6±6.7 | 8.0±6.3 | 9.8±7.9 | 11.2±7.3 | 12.0±3.7 | 0.174 |
| Preoperative SHIM score | 18.6±7.4 | 19.0±7.2 | 18.3±7.8 | 16.6±7.7 | 16.8±10.6 | 0.731 |
| Prostate weight (g) | 49.1±15.6 | 50.5±16.8 | 46.1±11.9 | 42.0±9.2 | 47.5±5.2 | 0.272 |
| Race | 0.056 | |||||
| White | 119 (85%) | 91 (88.4%) | 15 (71.4%) | 8 (72.7%) | 4 (80%) | |
| Black | 15 (10.7%) | 10 (9.7%) | 5 (23.8%) | 0 (0%) | 1 (20%) | |
| Asian | 6 (4.3%) | 2 (1.9%) | 1 (4.8%) | 3 (27.3%) | 0 (0%) | |
| Pathologic Gleason score | 1.000 | |||||
| 2–6 | 63 (45.0%) | 49 (47.6%) | 10 (47.6%) | 2 (18.2%) | 2 (40%) | |
| 7 | 60 (42.8%) | 43 (41.7%) | 8 (38.1%) | 8 (72.7%) | 1 (20%) | |
| 8–10 | 17 (12.2%) | 11 (10.7%) | 3 (14.3%) | 1 (9.1%) | 2 (40%) | |
| Pathologic stage | 1.000 | |||||
| ≤pT2 | 111 (79.3%) | 83 (80.6%) | 17 (81%) | 7 (63.6%) | 4 (80%) | |
| ⩾pT3 | 29 (20.7%) | 20 (19.4%) | 4 (19%) | 4 (36.4%) | 1 (20%) | |
| Positive surgical margin | 18 (12.8%) | 13 (12.6%) | 3 (14.3%) | 1 (9.1%) | 1 (20%) | 0.686 |
| Hospital stay (days) | 1.000 | |||||
| 1 | 131 (93.6%) | 96 (93.2%) | 21 (100%) | 10 (90.9%) | 4 (80%) | |
| 2 | 8 (5.7%) | 6 (5.8%) | 0 (0%) | 1 (9.1%) | 1 (20%) | |
| ⩾3 | 1 (0.7%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
Abbreviations: AUASS, American Urological Association Symptom Score; SHIM, Sexual Health Inventory for Men.
Group 1: the patients who were satisfied at both 3 and 12 months after surgery. Group 2: the patients who were satisfied at postop 3 months but dissatisfied at postop 12 months. Group 3: the patients who were dissatisfied at postop 3 months but satisfied at postop 12 months. Group 4: the patients who were dissatisfied at both 3 and 12 months after surgery.
*
P-value between four groups.